After revamping R&D in a global shakeup, Bayer prepping new labs for an expansion in cancer research at MIT
At Bayer, Pittsburgh is out, Cambridge, MA is in.
As part of a global shakeup that is costing 12,000 jobs, Bayer recently announced that it will shut down its old US HQ in Pennsylvania, axing hundreds of staffers. And that is happening while R&D is taking a big hit at the German multinational, with 900 researchers getting cut as Bayer completes the troublesome Monsanto acquisition.
But that doesn’t mean they’ve stopped adding research staff in the fields where they plan to grow.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.